3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
NIH
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Dermatologic
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Skin Neoplasms
1
Sarcoma, Kaposi
1
Melanoma
1
HIV Infections
1
Adenoviridae Infections
1
Acquired Immunodeficiency Syndrome
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
12
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
Tumor Necrosis Factor-alpha
×
Clear all
NCT05222932
2025-08-07
AVENTIL
TILT Biotherapeutics Ltd.
Phase 1
Active not recruiting
15 enrolled